Market Closed -
Bombay S.E.
06:00:52 2024-07-16 am EDT
|
5-day change
|
1st Jan Change
|
670.4
INR
|
+1.32%
|
|
-2.52%
|
-4.95%
|
Fiscal Period: March |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
15,344
|
14,449
|
21,658
|
-
|
-
|
Enterprise Value (EV)
1 |
15,344
|
14,449
|
19,845
|
21,658
|
21,658
|
P/E ratio
|
21.4
x
|
23.3
x
|
34.3
x
|
25.1
x
|
15.6
x
|
Yield
|
-
|
-
|
0.41%
|
0.45%
|
0.75%
|
Capitalization / Revenue
|
3.37
x
|
2.97
x
|
3.2
x
|
2.67
x
|
1.99
x
|
EV / Revenue
|
3.37
x
|
2.97
x
|
3.2
x
|
2.67
x
|
1.99
x
|
EV / EBITDA
|
11.7
x
|
11.8
x
|
13.8
x
|
10.5
x
|
7.6
x
|
EV / FCF
|
-404
x
|
-22.2
x
|
-11.7
x
|
34.5
x
|
305
x
|
FCF Yield
|
-0.25%
|
-4.5%
|
-8.54%
|
2.89%
|
0.33%
|
Price to Book
|
2.13
x
|
1.96
x
|
2.45
x
|
2.42
x
|
2.1
x
|
Nbr of stocks (in thousands)
|
31,398
|
31,398
|
32,290
|
-
|
-
|
Reference price
2 |
488.7
|
460.2
|
670.8
|
670.8
|
670.8
|
Announcement Date
|
5/28/22
|
5/27/23
|
5/18/24
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
4,554
|
4,871
|
6,196
|
8,111
|
10,899
|
EBITDA
1 |
-
|
1,315
|
1,223
|
1,442
|
2,061
|
2,851
|
EBIT
1 |
-
|
900.9
|
685.2
|
697
|
1,182
|
1,818
|
Operating Margin
|
-
|
19.78%
|
14.07%
|
11.25%
|
14.58%
|
16.68%
|
Earnings before Tax (EBT)
1 |
-
|
865.1
|
802
|
700.1
|
1,110
|
1,796
|
Net income
1 |
1,849
|
683.9
|
621.1
|
568.4
|
855.3
|
1,374
|
Net margin
|
-
|
15.02%
|
12.75%
|
9.17%
|
10.54%
|
12.61%
|
EPS
2 |
-
|
22.88
|
19.78
|
17.90
|
26.73
|
43.00
|
Free Cash Flow
1 |
-
|
-37.95
|
-650.6
|
-1,695
|
627
|
71
|
FCF margin
|
-
|
-0.83%
|
-13.36%
|
-27.36%
|
7.73%
|
0.65%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
30.43%
|
2.49%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
73.3%
|
5.17%
|
Dividend per Share
2 |
-
|
-
|
-
|
2.500
|
3.000
|
5.000
|
Announcement Date
|
8/3/21
|
5/28/22
|
5/27/23
|
5/18/24
|
-
|
-
|
Fiscal Period: March |
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
1,226
|
1,332
|
1,396
|
1,608
|
1,550
|
1,650
|
1,764
|
EBITDA
1 |
-
|
294.1
|
344.8
|
313.6
|
403
|
348
|
403
|
452.5
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
186
|
226
|
217
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
12%
|
13.7%
|
12.3%
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
153.4
|
136.4
|
189.2
|
146.4
|
203.5
|
146
|
153.5
|
174
|
Net margin
|
-
|
11.12%
|
14.2%
|
10.49%
|
12.66%
|
9.42%
|
9.31%
|
9.86%
|
EPS
|
-
|
-
|
-
|
-
|
7.400
|
5.350
|
5.000
|
5.500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/9/22
|
2/13/23
|
5/27/23
|
8/12/23
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-38
|
-651
|
-1,695
|
627
|
71
|
ROE (net income / shareholders' equity)
|
-
|
14.9%
|
8.73%
|
7.34%
|
10.2%
|
14.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
229.0
|
235.0
|
251.0
|
277.0
|
319.0
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1,322
|
1,414
|
1,939
|
1,551
|
1,875
|
Capex / Sales
|
-
|
29.03%
|
29.02%
|
31.29%
|
19.12%
|
17.2%
|
Announcement Date
|
8/3/21
|
5/28/22
|
5/27/23
|
5/18/24
|
-
|
-
|
Last Close Price
670.8
INR Average target price
927
INR Spread / Average Target +38.20% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.17% | 8.55B | | +87.40% | 4.63B | | +16.31% | 2.98B | | -3.15% | 2.65B | | -2.10% | 1.89B | | -53.27% | 1.81B | | -12.97% | 1.56B | | +21.59% | 1.27B | | -47.96% | 1.07B |
Medical & Diagnostic Laboratories
|